Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) shares traded up 0.1% during trading on Tuesday. The stock traded as high as $24.99 and last traded at $24.49. 969 shares were traded during trading, a decline of 49% from the average session volume of 1,899 shares. The stock had previously closed at $24.47.
Amplify Weight Loss Drug & Treatment ETF Stock Down 1.8%
The firm has a market capitalization of $5.58 million, a P/E ratio of 24.31 and a beta of 0.42. The firm has a 50 day moving average of $26.11 and a 200-day moving average of $25.28.
Amplify Weight Loss Drug & Treatment ETF Company Profile
The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
See Also
- Five stocks we like better than Amplify Weight Loss Drug & Treatment ETF
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Amplify Weight Loss Drug & Treatment ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Weight Loss Drug & Treatment ETF and related companies with MarketBeat.com's FREE daily email newsletter.
